ROCHESTER, Minn. — Mayo Clinic Comprehensive Cancer Center researchers will present their latest oncology findings at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled to be held May 30–June 3 at the McCormick Place Convention Center in Chicago. The event, recognized as one of the largest gatherings in the field of cancer research, will feature 59 Mayo Clinic-authored abstracts highlighting advancements in cancer care.

Among the standout presentations are practice-changing studies focused on chemotherapy approaches, artificial intelligence (AI) applications in oncology, cancer care at home and new therapies for breast cancer and melanoma — all focused on improving treatment options for patients with cancer.

Highlights include:

Plenary Session: Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage 3 deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)
Presentation time: Sunday, June 1, 1:05 to 1:17 p.m. CDT
Session title: Special Sessions
Presenter: Frank Sinicrope, M.D., medical oncologist and gastroenterologist

Clinical Science Symposium: Perception and concerns of the hematology and oncology (HemOnc) workforce about artificial intelligence (AI) in clinical practice (CliPr) and medical education (MedED)
Presentation time: Saturday, May 31, 2:03 to 2:15 p.m. CDT
Session title: The Future Is Now: Innovations in Medical Education
Presenter: Guilherme Sacchi de Camargo Correia, M.D., oncology fellow (senior author is Rami Manochakian, M.D., thoracic medical oncologist)

Oral Abstract Session: Tissue-free circulating tumor DNA assay and patient outcome in a phase 3 trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147)
Presentation time: Friday, May 30, 3:57 to 4:09 p.m. CDT
Session title: Gastrointestinal Cancer — Colorectal and Anal
Presenter: Frank Sinicrope, M.D., medical oncologist and gastroenterologist

Oral Abstract Session: [212Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after one-year follow-up and preliminary report for expansion participants.
Presentation time: Friday, May 30, 4:09 to 4:21 p.m. CDT
Session title: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
Presenter: Thorvardur Halfdanarson, M.D., medical oncologist       

Oral Abstract Session: NeoACTIVATE arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable stage 3 melanoma
Presentation time: Tuesday, June 3, 2025, 10:45 a.m. to 10:57 a.m. CDT
Session title: Melanoma/Skin Cancers
Presenter: Tina Hieken, M.D., breast and melanoma surgical oncologist

Poster Session: Cancer Care Beyond Walls (CCBW): A randomized pragmatic trial of home-based versus in-clinic cancer therapy administration
Session time: Sunday, June 1, 9 a.m. to noon CDT
Session title: Care Delivery and Quality Care
Presenter: Roxana Dronca, M.D., medical oncologist and the site deputy director of Mayo Clinic Comprehensive Cancer Center in Florida

Poster Session: A pilot single-arm, pragmatic trial in progress of in-home versus in-clinic subcutaneous nivolumab administration through Cancer Care Beyond Walls (CCBW) program (connected access and remote expertise)
Session time: Sunday, June 1, 9 a.m. to noon CDT
Session Title: Care Delivery/Models of Care
Presenter: Dina Elantably, M.B., B.CH., oncology fellow (senior author is Roxana Dronca, M.D., medical oncologist and the site deputy director of Mayo Clinic Comprehensive Cancer Center in Florida)

Poster Session: Initial results of MC200710 investigating therapeutic vaccine (PDS0101) alone or with pembrolizumab prior to surgery or radiation therapy for locally advanced HPV associated oropharyngeal carcinoma, a phase 2 window of opportunity trial
Session time: Monday, June 2, 9 a.m. to noon CDT
Session title: Head and Neck Cancer
Presenter: David Routman, M.D., radiation oncologist

Poster Session: ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study
Session time: Monday, June 2, 9 a.m. to noon CDT
Session title: Breast Cancer — Metastatic
Presenter: Tufia Haddad, M.D., medical oncologist

Poster Session: Estrogen receptor expression in residual breast cancer following neoadjuvant chemotherapy
Session time: Monday, June 2, 9 a.m. to noon CDT
Session title: Breast Cancer — Local/Regional/Adjuvant
Presenter: Sarah Premji, M.D., oncology fellow (senior author is Matthew Goetz, M.D., breast medical oncologist, and the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D.)

For more information about 2025 ASCO visit: https://www.asco.org/annual-meeting.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

About Mayo Clinic Comprehensive Cancer Center 
Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic Comprehensive Cancer Center is defining the cancer center of the future, focused on delivering the world's most exceptional patient-centered cancer care for everyone. At Mayo Clinic Comprehensive Cancer Center, a culture of innovation and collaboration is driving research breakthroughs in cancer detection, prevention and treatment to change lives.

Media contact on-site at ASCO:

• Kelley Luckstein, Mayo Clinic Communications, 507-202-8655, luckstein.kelley@mayo.edu

Related Articles